 The FDA has granted Sesen Bio Incs NASDAQ: SESN request for a Type A meeting to discuss the Chemistry, Manufacturing, and Controls CMC issues raised in the Complete Response Letter for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer. Related: Sesen Bio Stock Crashes As FDA Shoots Down Its Bladder Cancer Pitch. 